RecruitingPhase 2NCT07396324

Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

NEOadjuvant Iparomlimab and Tuvonralimab (QL1706) Plus Chemotherapy in Patients With Hormone Receptor Positive And HER2-Negative Breast Cancer: a Prospective, Single Arm, Multicenter Clinical Trial

Sponsor

RenJi Hospital

Enrollment

55 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

HR-positive,HER2-negative Breast Cancer

Summary

This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Carboplatin, a drug called Iparomlimab and Tuvonralimab, and others for people with hr-positive,her2-negative breast cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIparomlimab and Tuvonralimab

5.0mg/kg qw, start from C1D15

DRUGPaclitaxel

80mg/m\^2 qw

DRUGCarboplatin

AUC=1.5, D1, 8, 15, every 28 days

Locations(1)

Renji Hospital, School of Medicine, Shanghai Jiaotong University

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07396324

Related Trials

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

NCT067051271 location